secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001108205-25-000022
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis raises ~$10M; FY2024 net loss $43.4M; FDA/EMA see path for PCNSL drug
---------------------------------------------------------------------------

- Gross proceeds ~$10M from sale of 1.97M shares and pre-funded warrants for 2.18M shares, plus common warrants for 8.32M shares at $2.41.
- FY2024 net loss $43.4M ($6.88/share) vs $47.4M in 2023; revenue $10.9M vs $10.0M; cash $20.0M at Dec 31, 2024.
- Cash runway extended into Q4 2025 with offering net proceeds combined with existing cash.
- FDA and CHMP guidance supports potential accelerated/conditional approval for emavusertib in PCNSL; 9 of 13 BTKi-experienced evaluable patients had tumor reduction with 4 CRs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000022/0001108205-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000022/cris-20250328.htm
  HTML page:      https://secwatch.observer/filing/0001108205-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer